Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
NCT05471635 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 205
Last updated 2022-07-27
Summary
Vaccination coverage against COVID-19 differs widely between countries: in order to address this public health issue, this observational study seeks to understand whether there are any determinants/predictors. In order to highlight the presence of determinants and their strength in influencing vaccination coverage, all possible socio-demographic, economic, cultural, infrastructural and political variables considered capable of modifying such coverage were selected and analysed.
Conditions
- COVID-19 Vaccines
Interventions
- BIOLOGICAL
-
All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
Sponsors & Collaborators
-
Alberto Peano
lead OTHER
Principal Investigators
-
Maria M Gianino, Prof. · University of Turin, Department of Public Health Sciences and Pediatrics
-
Alberto Peano, Dr. · Department of Public Health Sciences and Pediatrics, University of Turin
-
Gianfranco Politano, PhD · Department of Control and Computer Engineering, Polytechnic University of Turin
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-06-20
- Primary Completion
- 2022-07-20
- Completion
- 2022-07-20
Countries
- Italy
Study Locations
More Related Trials
-
Testing the Persuasiveness of Pro-inoculation Arguments
NCT05804825 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT00474539 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4
NCT04559204 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine
NCT05477693 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT05092386 ·Status: COMPLETED ·Phase: PHASE1
-
Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
NCT00307541 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old
NCT04700618 ·Status: COMPLETED ·Phase: PHASE4
-
Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
NCT04275284 ·Status: COMPLETED
-
Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly
NCT02451969 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
NCT00574795 ·Status: COMPLETED ·Phase: PHASE3
-
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
NCT04551248 ·Status: UNKNOWN
-
Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China
NCT01451086 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366899 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine
NCT04989465 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers
NCT01485406 ·Status: COMPLETED ·Phase: PHASE1
-
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
NCT01444352 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccination Coverage and Level of Protection in Patients at Risk
NCT03820752 ·Status: COMPLETED
-
Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults
NCT04651790 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
NCT01193582 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
NCT01619462 ·Status: UNKNOWN ·Phase: PHASE3
-
Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants
NCT01262872 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage
NCT05920499 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults
NCT00197821 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
NCT01026038 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
NCT04398706 ·Status: COMPLETED ·Phase: PHASE2